The AMR Centre (AMRC), established three years as part of the UK’s response to the global threat from antimicrobial resistance, has pulled off something of a coup by bagging the rights to a promising novel monoclonal antibody from Japan's Shionogi & Co. Ltd..
The therapy, codenamed COT-143, is designed to help the body tackle Pseudomonas aeruginosa infections, a hard to treat drug-resistant superbug...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
